Scott will provide more details on our financial results, outlook, and capital allocation priorities.
And finally, I'll walk you through our 2022 objectives.
2021 was a transformative year for Albemarle.
For the year, excluding our fine chemistry services business, which was sold in June of 2021, we increased net sales by 11% to $3.3 billion, which was in line with our previous guidance.
Adjusted EBITDA grew 13% in 2021 to $871 million, surpassing the upper end of our guidance.
Now looking at Slide 5.
I'll begin on Slide 12.
For the fourth quarter, we generated net sales of $894 million, which is an increase of $15 million compared to the prior-year quarter.
